Xtant Medical (NYSEAMERICAN:XTNT) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Xtant Medical (NYSEAMERICAN:XTNT) posted its earnings results on Tuesday. The medical device company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02), Zacks reports. The business had revenue of $27.94 million during the quarter. Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. Xtant Medical updated its FY 2024 guidance to EPS.

Xtant Medical Trading Down 4.0 %

Shares of Xtant Medical stock traded down $0.02 during trading on Friday, reaching $0.43. 29,239 shares of the stock traded hands, compared to its average volume of 101,570. The firm has a market cap of $59.90 million, a price-to-earnings ratio of -3.31 and a beta of 0.39. Xtant Medical has a 52-week low of $0.43 and a 52-week high of $1.45. The company has a quick ratio of 1.01, a current ratio of 2.12 and a debt-to-equity ratio of 0.42.

Analyst Upgrades and Downgrades

Separately, Craig Hallum set a $1.50 target price on shares of Xtant Medical and gave the stock a “buy” rating in a report on Friday, October 18th.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.